It is our pleasure to share with you our Global Landscape of GLP Tox Outsourcing – A booming frontier for CROs.

GLP Tox outsourcing market is expected to touch ~$13B by 2028, driven by expanding R&D pipeline, including the rise in complex therapies. Tox testing, especially GLP Tox, remains one of the most commonly outsourced activities by biopharma.

To cater to the evolving needs of the biopharma industry, the CROs will need to expand to more specialized tox offerings, differentiated animal models, and a greater focus on therapeutic areas such as oncology, neurology, and rare diseases. Moreover, an integrated offering with strong bioanalytical services, innovative safety testing methods, and experience with complex modalities will be the key to gain competitive edge. Some of the CROs are already filling the gaps in their offerings through strategic initiatives, along with geographical expansion to gain proximity to the customers.

The attached presentation provides a global perspective of GLP Tox space along with the key initiatives some of the CROs are taking to capitalize on this opportunity.

You can download the presentation here.